



Combatting COVID-19 through Collaboration and Innovative Science

CONTRIBUTED BY ASTRAZENECA

**CHAIRMAN
LEVEL
SPONSOR**

**183RD
ANNUAL
DINNER**

SINCE THE START of the COVID-19 pandemic earlier this year, AstraZeneca – consistent with its values to follow the science, put patients first, and do the right thing – has progressed a number of initiatives to ensure the continued supply of its medicines to patients, to safeguard the health and wellbeing of all its employees and communities, and to make available a potential vaccine or treatment options for the virus.

To help contain the spread of the virus early on in the pandemic, AstraZeneca donated nine million face masks to support health care workers around the world, and partnered with the World Economic Forum's COVID Action Platform to identify the countries in greatest need. In the US, AstraZeneca donated to the CDC Foundation to expand US testing and data capabilities and deploy emergency staffing on the front lines at the state and local level.

In late April, AstraZeneca secured a landmark partnership with the University of Oxford for the global development, production and supply of their potential COVID-19 vaccine. At that time, the Company made a commitment to ensure broad and equitable supply of the vaccine throughout the world at no profit during the pandemic, should it prove safe and effective. To deliver on this commitment, AstraZeneca has strategically focused on partnering with governments, multilateral organizations and manufacturers to establish agreements for the distribution of the vaccine, if approved.

As of the end of July, the Company secured agreements for more than two billion doses of the vaccine with the UK and US governments, Europe's Inclusive Vaccines Alliance, the Coalition for Epidemic Preparedness (CEPI), GAVI the Vaccine Alliance, the Serum Institute of

India, and R-Pharm in Russia. AstraZeneca is working to secure additional agreements as well.

Beyond the vaccine, AstraZeneca mobilized global research efforts to discover novel coronavirus-neutralizing antibodies to prevent and treat progression of the COVID-19 disease. The Company signed agreements with academia and US government agencies and is progressing a combination approach consisting of a pair of monoclonal antibodies. Additionally, AstraZeneca is testing new and existing medicines in its portfolio across multiple therapy areas to treat the infection.

To support patients, AstraZeneca's AZ&Me program, which for more than 40 years has provided eligible patients (uninsured, underinsured and Medicare) with AstraZeneca medicines at no cost, has put proactive measures in place to minimize any potential impact to enrolled patients. This includes sending additional doses of product with patients' refills, and in some instances, shipping refills to patients earlier than scheduled – with the hope that these actions will ensure patients have uninterrupted access to their medication while providing peace of mind during this uncertain time.

AstraZeneca is a global, science-led biopharmaceutical company focused on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. With its North American headquarters in Wilmington, Del., AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information on AstraZeneca please visit www.astrazeneca-us.com. ■